Auteur M. E. SOCIAS

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

Buprenorphine/naloxone vs methadone for the treatment of opioid use disorder

B. NOSYK ; J. E. MIN ; F. HOMAYRA ; M. KURZ ; B. C. GUERRA-ALEJOS ; R. YAN ; M. PISKE ; S. R. SEAMAN ; P. BACH ; S. GREENLAND ; M. E. KARIM ; U. SIEBERT ; J. BRUNEAU ; P. GUSTAFSON ; K. KAMPMAN ; P. T. KORTHUIS ; T. LOUGHIN ; L. C. MCCANDLESS ; R. W. PLATT ; K. T. SCHNEPEL ; M. E. SOCIAS | 2024
Dans Journal of the American Medical Association (Vol.332, n°21, December 3, 2024) Article : Périodique

Key points: Question: Is buprenorphine/naloxone associated with lower risk of treatment discontinuation and mortality compared with methadone? Findings: In this population-based retrospective cohort study that included 30?891 individuals initi[...]

Plus d'info

Ajouter à la sélection

Lien externe

Comparative effectiveness of urine drug testing schedules alongside opioid agonist treatment: Emulation of a population-based target trial in British Columbia, Canada

M. KURZ ; B. C. GUERRA-ALEJOS ; J. E. MIN ; S. R. SEAMAN ; M. PISKE ; P. BACH ; J. BRUNEAU ; S. GREENLAND ; P. GUSTAFSON ; K. KAMPMAN ; M. E. KARIM ; P. T. KORTHUIS ; R. W. PLATT ; U. SIEBERT ; M. E. SOCIAS ; E. WOOD ; B. NOSYK | 2025
Dans Addiction (Vol.120, n°12, December 2025) Article : Périodique

BACKGROUND AND AIM: Urine drug testing is often utilized alongside opioid agonist treatment to assess client progress by validating self-reported substance use, monitoring for diversion and supporting clinical decisions for take-home dosing. How[...]

Plus d'info

Ajouter à la sélection

Lien externe

Epidemic of deaths from fentanyl overdose [Editorial]

M. E. SOCIAS ; E. WOOD | 2017
Dans British Medical Journal (Vol.358, n°8126, 21 October 2017) Article : Périodique

Another serious side effect of the war on drugs. Strategies to tackle the harms of substance misuse and addiction remain among the most controversial areas in public policy. Although new ways of thinking are slowly emerging, the overwhelming mo[...]

Plus d'info

Ajouter à la sélection

Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review

M. E. SOCIAS ; M. KARAMOUZIAN ; S. PARENT ; J. BARLETTA ; K. BIRD ; L. TI | 2019
Dans International Journal of Drug Policy (Vol.72, October 2019) Article : Périodique

Background: Despite the key role that people who inject drugs (PWID) play in the hepatitis C virus (HCV) epidemic, HCV treatment rates among this population have been historically low. Integrated models of HCV and substance use care have the pot[...]

Plus d'info

Ajouter à la sélection

Integrating hepatitis C and addiction care for people who inject drugs in the era of direct-acting antiviral therapy

K. BIRD ; M. E. SOCIAS ; L. TI | 2018
Dans International Journal of Drug Policy (Vol.59, September 2018) Article : Périodique

As new, more tolerable and effective hepatitis C virus (HCV) treatments are available, there is a global need to consider how to maximize treatment access for groups who are most affected by HCV. A substantial number of people who inject drugs ([...]

Plus d'info

Ajouter à la sélection

Prevalence and correlates of intentional substance use to reduce illicit opioid use in a Canadian setting

J. KLIMAS ; W. Y. MOK ; S. LAKE ; M. E. SOCIAS ; K. DEBECK ; K. HAYASHI ; E. WOOD ; M. J. MILLOY | 2022
Dans Journal of Substance Use (Vol.27, n°3, June 2022) Article : Périodique

Background: While preliminary evidence has begun to document intentional use of one substance to reduce the use of another, the phenomenon of drug substitution among people who use illicit opioids remains understudied. Therefore, we sought to es[...]

Plus d'info

Ajouter à la sélection

Lien externe